A never ending story.
In March 2010 Echolight srl was officially incorporated by the founding team with a revolutionary idea: developing the first radiation free device for early diagnosis of osteoporosis at lumbar vertebrae and femoral neck.
It is officially filed the first patent of EchoSound technology: an innovative echographic approach for bone micro-architecture characterization.
Life Science Capital
Life Science Capital S.p.a., an italian investment company in the medical device sector, invests in Echolight to support and speed up the research and development activities of the company.
The first version of Echos is finalized: the only radiation free device for bone densitometry at lumbar vertebrae and femoral neck. A decisive step towards a new era in the early diagnosis of osteoporosis.
In collaboration with the National Council of Research the first multi-center study for the clinical validation of the new device in the most important reference centers for the diagnosis of osteoporosis is launched.
Echolight secured all the standard certifications: UNI CEI EN ISO 13485: 2012, ISO 13485: 2003, UNI EN ISO 9001: 2008 Quality Management System and the CE mark for Echos, EchoStation and EchoStudio by KIWA CERMET.
Echolight introduces to the international medical community the latest release of Echos at the World Congress of Osteoporosis.
Panakès and Invitalia Ventures have co-led an investment round in Echolight, in order to support the clinical validation of the innovative technology and the worldwide launch of the product.
Echolight at the International Trade Fair MEDICA launched Echos after extensive research and development activities carried out over the last eight years.
Echolight established the new international scientific advisory board with the most important medical personalities in the diagnosis of osteoporosis : Prof. Maria Luisa Brandi, Prof. Cyrus Cooper, Prof. Adolfo Diez-Perez, Prof. Jean-Yves Reginster and Prof. Renè Rizzoli.
R.E.M.S Multicenter Clinical Trial
Milestone pubblication on Osteoporosis International about R.E.M.S. Multicenter Clinical Trial: “Radiofrequency echographic multispectrometry compared with dual X-ray absorptiometry for osteoporosis diagnosis on lumbar spine and femoral neck.”
Echolight S.p.A. has received 510(k) clearance from the Food and Drug Administration (FDA) to market its range of products in the U.S.A.